Multi- and poly-pharmacology of carbonic anhydrase inhibitors
Pharmacological Reviews,
Год журнала:
2024,
Номер
77(1), С. 100004 - 100004
Опубликована: Сен. 26, 2024
Eight
genetically
distinct
families
of
the
enzyme
carbonic
anhydrase
(CA,
EC
4.2.1.1)
have
been
described
in
organisms
overall
phylogenetic
tree.
They
catalyze
hydration
CO2
to
bicarbonate
and
protons
are
involved
pH
regulation,
chemosensing,
metabolism.
The
15
α-CA
isoforms
present
humans
pharmacological
drug
targets
known
for
decades,
their
inhibitors
being
used
as
diuretics,
antiglaucoma,
antiepileptic,
or
antiobesity
drugs,
well
management
acute
mountain
sickness,
idiopathic
intracranial
hypertension,
recently,
antitumor
theragnostic
agents.
Other
potential
applications
include
use
CA
(CAIs)
inflammatory
conditions,
cerebral
ischemia,
neuropathic
pain,
Alzheimer/Parkinson
disease
management.
CAs
from
pathogenic
bacteria,
fungi,
protozoans,
nematodes
started
be
considered
recent
years,
with
notable
advances
registered.
CAIs
a
complex
multipharmacology
probably
unique
this
enzyme,
which
has
exploited
intensely
but
may
lead
other
relevant
future
due
emergence
design
approaches
that
afforded
highly
isoform-selective
compounds
most
α-CAs
date.
belong
multitude
chemical
classes
(sulfonamides
isosteres,
[iso]coumarins
related
compounds,
mono-
dithiocarbamates,
selenols,
ninhydrines,
boronic
acids,
benzoxaboroles,
etc).
polypharmacology
will
also
discussed
because
drugs
originally
discovered
treatment
non-CA
conditions
(topiramate,
zonisamide,
celecoxib,
pazopanib,
thiazide,
high-ceiling
diuretics)
show
effective
inhibition
against
many
CAs,
led
repurposing
diverse
applications.
SIGNIFICANCE
STATEMENT:
multiple
pharmacologic
applications,
such
antiobesity,
antiacute
anti-idiopathic
drugs.
Their
neurodegenerations
investigated
recently.
Parasite
anhydrases
anti-infectives
novel
mechanisms
action
can
bypass
resistance
commonly
Drugs
effectively
inhibit
these
enzymes
exert
interesting
polypharmacologic
effects.
Язык: Английский
Drug interactions of carbonic anhydrase inhibitors and activators
Expert Opinion on Drug Metabolism & Toxicology,
Год журнала:
2024,
Номер
20(3), С. 143 - 155
Опубликована: Март 3, 2024
Introduction
Carbonic
anhydrases
(CAs,
EC
4.2.1.1)
have
been
established
drug
targets
for
decades,
with
their
inhibitors
and
activators
possessing
relevant
pharmacological
activity
applications
in
various
fields.
At
least
11
sulfonamides/sulfamates
are
clinically
used
as
diuretics,
antiglaucoma,
antiepileptic,
or
antiobesity
agents
one
derivative,
SLC-0111,
is
clinical
trials
antitumor/antimetastatic
agent.
The
were
less
investigated
no
Язык: Английский
Next generation sequencing-based transcriptome data mining for virus identification and characterization: review on recent progress and prospect
Journal of Clinical Virology Plus,
Год журнала:
2024,
Номер
unknown, С. 100194 - 100194
Опубликована: Сен. 1, 2024
Язык: Английский
What have we learnt from the COVID-19 pandemic?
Elsevier eBooks,
Год журнала:
2025,
Номер
unknown, С. 867 - 892
Опубликована: Янв. 1, 2025
Язык: Английский
Utility of Protein Markers in COVID-19 Patients
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(2), С. 653 - 653
Опубликована: Янв. 14, 2025
COVID-19
has
been
a
challenge
at
the
healthcare
level
not
only
in
early
stages
of
pandemic,
but
also
subsequent
appearance
long-term
COVID-19.
Several
investigations
have
attempted
to
identify
proteomic
biomarkers
an
attempt
improve
clinical
care,
guide
treatment
and
predict
possible
patient
outcomes.
Proteins
such
as
C-reactive
protein
(CRP)
or
interleukin
6
(IL-6)
are
clear
markers
severe
disease,
many
others
proposed
that
could
help
risk
stratification
prediction
specific
complications.
This
review
aims
bring
together
most
relevant
studies
this
regard,
providing
information
notable
relation
found
date.
Язык: Английский
Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 14, 2025
Abstract
Community-acquired
pneumonia
(CAP)
has
a
significant
impact
on
public
health,
especially
in
light
of
the
recent
SARS-CoV-2
pandemic.
To
enhance
disease
characterization
and
improve
understanding
underlying
mechanisms,
comprehensive
analysis
plasma
lipidome,
metabolome
proteome
was
conducted
patients
with
viral
bacterial
CAP
infections,
including
those
induced
by
SARS-CoV-2.
Lipidomic,
metabolomic
proteomic
profiling
were
samples
69
suffering
either
from
or
CAP.
Lipid
metabolite
analyses
LC-MS-based,
while
performed
using
multiple
panels
Olink
platform.
Statistical
methods,
machine
learning
pathway
investigating
differences
between
infection
types.
Through
comparison
pathogen
groups,
distinct
signatures
observed
profiles.
Notably,
linoleic
acid-derived
inflammation
signaling
metabolites
(EpOME
DiHOME)
increased
compared
to
Similarly,
proteins
involved
cellular
immune
response
apoptosis
(LAG-3
TRAIL)
showed
elevated
levels
CAP,
exhibited
notable
elevation
pattern-recognizing
receptors
(CLEC4D
EN-RAGE).
Additionally,
within
lipidomic
profile
at
baseline,
several
lipids
displayed
pneumonia,
bile
acids
(GCA,
TCA,
TCDCA),
various
tri-
diglycerides
(TGs
DGs),
phosphatidylcholines
(PCs).
These
findings
hold
promise
for
facilitating
differential
diagnosis
pulmonary
infections
based
systemic
proteome,
enabling
timely
treatment
decisions.
they
highlight
potential
targets
drug
research,
advancing
therapeutic
interventions
By
providing
valuable
insights
into
molecular
this
study
contributes
improvement
and,
ultimately,
development
effective
strategies.
Язык: Английский
Implementation of multiomic mass spectrometry approaches for the evaluation of human health following environmental exposure
Molecular Omics,
Год журнала:
2024,
Номер
20(5), С. 296 - 321
Опубликована: Янв. 1, 2024
This
review
introduces
advancements
in
multiomic
mass
spectrometry
which
revolutionized
our
knowledge
of
complex
biological
processes
across
scientific
disciplines,
exposure
scenarios,
and
diseases,
benefiting
diagnostic
treatment
strategies.
Язык: Английский
The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(16), С. 8633 - 8633
Опубликована: Авг. 8, 2024
While
COVID-19’s
urgency
has
diminished
since
its
emergence
in
late
2019,
it
remains
a
significant
public
health
challenge.
Recent
research
reveals
that
the
molecular
intricacies
of
this
virus
are
far
more
complex
than
initially
understood,
with
numerous
post-translational
modifications
leading
to
diverse
proteoforms
and
viral
particle
heterogeneity.
Mass
spectrometry-based
proteomics
patient
serum/plasma
emerges
as
promising
complementary
approach
traditional
diagnostic
methods,
offering
insights
into
SARS-CoV-2
protein
dynamics
enhancing
understanding
disease
long-term
consequences.
This
article
highlights
key
findings
from
three
years
pandemic-era
research.
It
delves
biomarker
discovery,
advancements,
drug
development
efforts
aimed
at
monitoring
COVID-19
onset
progression
exploring
treatment
options.
Additionally,
examines
global
abundance
modification
profiling
elucidate
signaling
pathway
alterations
protein-protein
interactions
during
infection.
Finally,
explores
potential
emerging
multi-omics
analytic
strategies
combatting
SARS-CoV-2.
Язык: Английский